What Laboratorio Pablo Cassará does

Laboratorio Pablo Cassará is a privately held, family-owned Argentine pharmaceutical company founded in 1948 and headquartered in Buenos Aires (Av. Gral. Paz 14268), employing between 501 and 1,000 people. It operates across the full pharmaceutical value chain — R&D through industrial manufacturing — on 30,000 m² of GMP PIC/S certified production capacity, manufacturing unconventional dosage forms including inhaled aerosols, powder inhalers, lyophilized biologics, viral vaccines, and preservative-free sterile multidosis products. The company distributes its portfolio through Argentina's national pharmacy network and selected hospital channels, with secondary distribution reaching Central America, North America, and Asia.

The core product portfolio is horizontally diversified across dermatology, respiratory, pediatrics, otorhinolaryngology, nephrology, probiotics, diagnostics, and vaccines, including specialty brands such as Aerotrop (bronchodilator), the Medisol sub-brand of affordable essential medicines, and Hepatitis B (AGB) and COVID-19 (ARVAC Cecilia Grierson) recombinant vaccines. The company's most differentiated assets are three advanced-therapy platforms: VACCIMEL, an allogeneic cellular immunotherapy vaccine for cutaneous melanoma with reported 96-month median metastasis-free survival; NIODERM, an ANMAT-registered autologous dermo-epidermal skin substitute on a porcine pericardium matrix; and a pipeline of seven biosimilar medicines, one monoclonal antibody under patent, and a bio-printing organ platform for autografts. Research is anchored in a 30-year applied biotechnology program involving Fundación Pablo Cassará, CIRES, and ICT Milstein — the latter a 2007 public-private partnership with CONICET, the first of its kind in Argentina.

Revenue is generated primarily through one-time unit sales of prescription and OTC pharmaceutical products at publicly listed Argentine peso prices, with a discount coupon program accessible through the company's digital platform. The customer base spans the general population through pharmacy distribution, underserved populations through the Medisol social-pricing line, and specialized clinical users (oncology centers, burn units) for advanced therapies. The company is closely held by Argentine family capital with no disclosed institutional investors, funding rounds, or M&A activity.

Name

Laboratorio Pablo Cassará

Legal name

Laboratorio Pablo Cassará

Website

https://cassara.com.ar

Company type

Private

Founded year

1948

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Laboratorio Pablo Cassará is a family-owned Argentine pharmaceutical manufacturer founded in 1948, producing a diversified portfolio of prescription, OTC, and advanced biotherapeutic products across dermatology, respiratory, vaccines, and oncology, distributed primarily through Argentina's national pharmacy network and select international markets.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB)

akta.pro secondary industry

Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable) (HLAAAEAJ)

Keywords

• Pharmaceutical manufacturing
• Biotechnology medicines
• Cellular immunotherapy
• Recombinant vaccines
• Prescription drugs

Headquarters

HQ city

Buenos Aires, Ciudad de Buenos Aires

HQ country

Argentina

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Sale of prescription and OTC pharmaceutical products across therapeutic categories including dermatology, respiratory, pediatrics, nephrology, vaccines, probiotics, and diagnostics. Products are distributed through the national pharmacy network and hospital channels.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Laboratorio Pablo Cassará is an Argentine pharmaceutical company that manufactures and distributes a broad portfolio of prescription and OTC medicines across dermatology, respiratory, pediatrics, otorhinolaryngology, nephrology, probiotics, vaccines, diagnostics, and advanced therapies. The company operates GMP PIC/S certified manufacturing facilities producing unconventional pharmaceutical forms including inhaled aerosols, lyophilized biologics, viral vaccines, and preservative-free sterile products, while also developing biotechnological medicines such as cellular immunotherapy (Vaccimel), autologous skin substitutes (NIODERM), and recombinant vaccines (ARVAC).

Product overview

Laboratorio Pablo Cassará is an Argentine family-owned pharmaceutical company founded in 1948 focused on human health, with strong emphasis on technological development. The company operates as a diversified pharmaceutical portfolio spanning multiple therapeutic areas: a broad Respiratory Products Line (inhaled corticosteroids, bronchodilators, combination inhalers, nasal sprays), Dermatology products (topical corticosteroids, antifungals, retinoids, sunscreens, acne treatments), Pediatrics medications, Otorhinolaryngology (ear and nasal products), Nephrology (erythropoietin, calcium supplements, anticoagulants), a Vaccines division (hepatitis B recombinant vaccines, COVID-19 ARVAC protein vaccine), an Oncology/Advanced Therapies division (Vaccimel melanoma cellular immunotherapy vaccine, NIODERM autologous skin substitute), Diagnostics (Kitan D olfactory evaluation kit, Neokit COVID-19 test), Probiotics (Biocass, Polimix, Inufiber), the Medisol social-responsibility sub-brand of affordable essential medicines, and Enov Nutributter nutritional supplement. The company also operates under GMP PIC/S standards across 30,000 m² of automated manufacturing areas.

Differentiator

Problem solved

Functional benefit

Brands

• MEDISOL: A line of national production medicines designed for primary health care for children and adults in outpatient pathologies, offering accessible medication to the entire Argentine population. Launched in 1999 as part of corporate social responsibility.

Products and services

• Aerotrop

Quantifiable outcome

• VACCIMEL prolongs median metastasis-free survival to 96 months compared to 13 months with IFNα2b in adjuvant melanoma treatment
• +2 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• ICT Milstein (CONICET + Fundación Pablo Cassará)coreStrategic or Co-development Partner · 1 January 2007A dual-dependence execution unit created in 2007 as a result of the integration of CONICET and Fundación Pablo Cassará, being the first public-private fusion precedent in Argentina. The institute conducts advanced biotechnology research.
• Fundación Pablo CassarácoreStrategic or Co-development PartnerThe Pablo Cassará Foundation, with over 30 years of life, has built a recognized space for the development of scientific and technological research projects in the country. Hosts multiple research groups including viral vaccines, CEBIR, biofarmacos, plant micropropagation, and advanced therapies.
• CIRES (Centro de Investigación Respiratoria Infantil)minorStrategic or Co-development PartnerA center dedicated to research in the area of respiratory diseases in children, staffed by four pediatric pulmonology specialists.
• World Health Organization (WHO)coreStrategic or Co-development PartnerWHO recommended and tested the Enov Nutributter lipid-based nutritional supplement for childhood malnutrition intervention.
• UNICEFcoreStrategic or Co-development PartnerUNICEF tested and approved the Enov Nutributter lipid-based nutritional supplement as a tool to address childhood malnutrition in Argentina.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• mAbxience: mAbxience is a biologics company with Argentine roots that develops and manufactures biosimilars for global markets. Cassará overlaps through its seven-medicine biosimilar platform, recombinant biologics capabilities and regulated manufacturing footprint.
• Celltrion: Celltrion is a global biopharmaceutical company centered on biosimilar and innovative biologic development and manufacturing. Cassará's biosimilar pipeline, monoclonal-antibody work and in-house biomanufacturing create direct category overlap despite the difference in scale.
• Bavarian Nordic: Bavarian Nordic develops vaccines and immunotherapies, including approaches designed to stimulate immune responses against disease and cancer. Its vaccine and immuno-oncology platform is particularly comparable to Cassará's ARVAC and VACCIMEL assets.
• Laboratorios Bagó: Laboratorios Bagó is an Argentine pharmaceutical company spanning prescription, hospital, OTC and biotechnology products. Its broad portfolio and manufacturing operations make it a relevant peer for Cassará's diversified domestic pharmaceutical business.
• Laboratorios Richmond: Laboratorios Richmond is an Argentine pharmaceutical company involved in drug development and manufacturing, including vaccine-related products. It is comparable to Cassará as a domestic, science-oriented pharma manufacturer serving both institutional and prescription markets.
• Sinergium Biotech: Sinergium Biotech is an Argentine biotechnology company focused on developing and manufacturing vaccines and other biological products. It closely matches Cassará's combination of local scientific capabilities, vaccine technology and regulated biomanufacturing.
• Laboratorios Gador: Laboratorios Gador is an established Argentine pharmaceutical company with a broad prescription portfolio and domestic manufacturing presence. It competes with Cassará across therapeutic categories while providing a close regional benchmark for specialty and hospital products.

Broad incumbents

• CSL: CSL is a global biotechnology company with major vaccines and specialty biotherapeutics businesses supported by regulated manufacturing. It is a broad incumbent benchmark for Cassará's vaccine, biologic and plasma-related advanced-therapy capabilities.
• Roemmers: Roemmers is one of Argentina's established pharmaceutical manufacturers, with a wide portfolio across prescription and consumer-health categories. Its scale and breadth provide a relevant benchmark for Cassará's established branded and specialty pharmaceutical operations.
• Laboratorio Elea Phoenix: Laboratorio Elea Phoenix is a broad Argentine pharmaceutical company with prescription, hospital, OTC and consumer-health offerings. It is comparable to Cassará through its domestic channel reach, broad therapeutic portfolio and local production base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/laboratorio-pablo-cassara

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Laboratorio Pablo Cassará